Recruiting

Testing a New Cancer-Fighting Pill in Advanced Solid Tumors

Plain-English translation of NCT07923214 on ClinicalTrials.gov ↗ · Source last updated November 2026 · Translation generated November 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This Phase I trial is testing a new medication called , which is designed to fight advanced cancers by targeting proteins that help cancer cells grow. Researchers will gradually increase the dose to find the highest safe dose and watch how your body handles the medication. Lab studies have shown promise in breast cancer, ovarian cancer, and gastric cancer, so now doctors are testing it in real patients.

Many patients with advanced solid tumors run out of effective treatment options, and existing therapies don't work for everyone. This medication represents a new approach to treating these cancers, and this early-stage trial will help doctors understand whether this treatment is safe enough and effective enough to pursue further.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with an advanced or metastatic solid tumor (such as breast, ovarian, gastric cancer, or other solid tumors) that has stopped responding to standard treatments, or you cannot tolerate standard treatments
you have a life expectancy of at least 12 weeks
your overall health and energy level allow you to manage daily activities with minimal assistance (ECOG status 0–1)
you are willing to provide a tumor tissue sample (from an archive or fresh biopsy) and agree to use effective contraception for at least 6 months after your last dose

You likely don't qualify if…

you have received cancer treatment (chemotherapy, targeted therapy, immunotherapy, or radiation) within the past 4 weeks
you are currently taking certain medications that interact with this one (strong CYP3A4 or CYP2C8 inhibitors)
you have active cancer in your brain or brain metastases that did not respond to previous local treatment
you have serious heart disease, uncontrolled nausea or vomiting, chronic diarrhea, or conditions that prevent your body from absorbing medications properly
you are pregnant, breastfeeding, or unwilling to use contraception for the required period

What participation looks like

You will take capsules of the medication by mouth twice a day in 28-day cycles. The study starts with a single dose on Day 1 to observe how your body responds, then you'll continue taking it daily. The dose will be gradually increased across different patient groups to find the safest and most effective level. Throughout the study, you'll have regular visits for blood tests, imaging scans, and check-ups to monitor how well the medication is working and how your body is tolerating it.

AI-generated summary from trial data · Nov 10, 2026 · Not medical advice

Trial locations(4 sites)

China

Fujian Cancer Hospital, Fuzhou, Fujian

Zhongshan Hospital of Dalian University, Dalian, Liaoning

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality

West China Hospital, Sichuan University, Chengdu, Sichuan